(E)-1,3,5-trimethyl-6-styryl-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: (E)-1,3,5-trimethyl-6-styryl-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione
• 英文别名: 1,3,5-Trimethyl-6-((E)-styryl)-1,5-dihydro-pyrrolo[3,2-d]pyrimidine-2,4-dione；1,3,5-trimethyl-6-[(E)-2-phenylethenyl]pyrrolo[3,2-d]pyrimidine-2,4-dione
• 化学式: C₁₇H₁₇N₃O₂
• 分子量: 295.341
• InChiKey: CPTGMMDIEVVMQA-MDZDMXLPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  45.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1,3,4-三甲基尿嘧啶 在 氢氧化钾 、 硫酸 、 硝酸 、 sodium methylate 、 potassium carbonate 、 N,N-二甲基甲酰胺 、 potassium iodide 作用下， 以 甲醇 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.25h， 生成 (E)-1,3,5-trimethyl-6-styryl-1H-pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione
  参考文献：
  名称：

  Synthesis and Structure-Activity Relationships of Deazaxanthines: Analogs of Potent A1- and A2-Adenosine Receptor Antagonists

  摘要：

  A set of 22 9-deazaxanthines (pyrrolo[3,2-d]pyrimidine-2,4-diones) and three 7-deazaxanthines (pyrrolo[2,3-d] pyrimidine-2,4-diones) with various substituents in the 1-, 3-, 7- or 9-, and 8-positions was synthesized and investigated in A1 and A2a adenosine receptor binding assays at rat brain cortical membranes and rat brain striatal membranes, respectively. 9-Deazaxanthines showed structure-activity relationships that were similar to those of xanthines. They were about equipotent to the corresponding xanthines at A2a adenosine receptors. 9-Deazaxanthines were generally at least 2-3-fold more potent than xanthines at A1 receptors and therefore exhibited higher A1 selectivities compared to the xanthines. 1,3-Dimethyl-8-(2-naphthyl)-9-deazaxanthine (19e) showed high affinty (K-i = 26 nM) and selectivity for A1 adenosine receptors. A hydroxyl function at N7 of 9-deazaxanthines was unfavorable for A1 and A2a receptor binding. 7-Deazaxanthines were considerably less potent compared to xanthines and to 9-deazaxanthines at both receptor subtypes.

  DOI：

  10.1021/jm00036a019

文献信息

• Divergent synthesis of novel 9-deazaxanthine derivatives via late-stage cross-coupling reactions
  作者：Francesca Bartoccini、Giovanni Piersanti、Marco Mor、Giorgio Tarzia、Patrizia Minetti、Walter Cabri

  DOI：10.1039/c2ob26516h

  日期：——

  A small library of 8-substituted 9-deazaxanthines has been prepared by late-stage diversification of an 8-bromo-9-deazaxanthine. By utilizing palladium-catalyzed cross-coupling reactions a single key precursor can be transformed into a variety of 8-substituted-9-deazaxanthine compounds. Three key 8-bromo-9-deazaxanthine intermediates were efficiently prepared from commercially available 6-chlorouracil in six steps.

  通过对8-溴-9-去氨黄素的后期多样化，制备了一小库8-取代的9-去氨黄素。利用钯催化的交叉偶联反应，可以将一个单一的关键前体转化为多种8-取代的9-去氨黄素化合物。三个关键的8-溴-9-去氨黄素中间体通过六步反应高效地从商业可得的6-氯尿嘧啶制备而成。
• Synthesis of (<i>E</i>)-8-(3-Chlorostyryl)caffeine Analogues Leading to 9-Deazaxanthine Derivatives as Dual A_2A Antagonists/MAO-B Inhibitors
  作者：Silvia Rivara、Giovanni Piersanti、Francesca Bartoccini、Giuseppe Diamantini、Daniele Pala、Teresa Riccioni、Maria Antonietta Stasi、Walter Cabri、Franco Borsini、Marco Mor、Giorgio Tarzia、Patrizia Minetti

  DOI：10.1021/jm301686s

  日期：2013.2.14

  A systematic modification of the caffeinyl core and substituents of the reference compound (E)-8-(3-chlorostyryl)caffeine led to the 9-deazaxanthine derivative (E)-6-(4-chlorostyryl)-1,3,5,=trimethyl-1H-pyrrolo[3,2-d]pyrimidine-2,4-(3H,5H)-dione (17f), which acts as a dual human A(2a) antagonist/MAO-B inhibitor (K-i(A(2A)) = 260 nM; IC50(MAO-B) = 200 nM; IC50(MAO-A) = 10 mu M) and dose dependently counteracts haloperidol-induced catalepsy in mice from 30 mg/kg by the oral route. The compound is the best balanced A(2A) antagonist/MAO-B inhibitor reported to date, and it could be considered as a new lead in the field of anti-Parkinson's agents. A number of analogues of 17f were synthesized and qualitative SARs are discussed. Two analogues of 17f, namely 18b and 19a, inhibit MAO-B with IC50 of 68 and 48 nM, respectively, being 5-7-fold more potent than the prototypical MAO-B inhibitor deprenyl (IC50 = 334 nM).